Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v4-FR Version v3-EN
Language French English
Date Updated 2024-03-13 2024-03-13
Drug Identification Number 02484013 02484013
Brand name BRINEURA BRINEURA
Common or Proper name CERLIPONASE ALFA INJECTION CERLIPONASE ALFA INJECTION
Company Name BIOMARIN INTERNATIONAL LIMITED BIOMARIN INTERNATIONAL LIMITED
Ingredients CERLIPONASE ALFA CERLIPONASE ALFA
Strength(s) 150MG 150MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRACEREBROVENTRICULAR INTRACEREBROVENTRICULAR INTRACEREBROVENTRICULAR INTRACEREBROVENTRICULAR
Packaging size Each pack contains two vials, each containing 150 mg/5 ml cerliponase alfa, and one vial 5 ml of flushing solution Each pack contains two vials, each containing 150 mg/5 ml cerliponase alfa, and one vial 5 ml of flushing solution
ATC code A16AB A16AB
ATC description
Reason for shortage Requirements related to complying with good manufacturing practices. Requirements related to complying with good manufacturing practices.
Anticipated start date 2024-08-05 2024-08-05
Actual start date
Estimated end date Unknown Unknown
Actual end date
Shortage status Anticipated shortage Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments